Back    Zoom +    Zoom -
<Results>INSILICO Annual Loss Widens Sharply to US$352M
Recommend
1
Positive
3
Negative
3
INSILICO (03696.HK), a company focused on AI-empowered drug development, announced its 2025 results, reporting a total revenue for the year of US$56.239 million, down approx. 34.5% YoY.

The Company recorded a loss of US$352.3 million, expending by 19.6x from a loss of US$17.096 million in 2024. Basic loss per share was US$4.48, a significant increase from US$0.24 in 2024. No dividend was declared.

Related News Insilico Medicine (03696.HK) Expands Annual Loss to USD352 Million

AASTOCKS Financial News
Website: www.aastocks.com